Year: 2026
Type: preprint
Abstract: Multiple sclerosis therapies remain confined to immunomodulatory agents that reduce inflammatory activity; none restores lost myelin, and disability can continue to accumulate independently of relapses. Development of remyelinating therapies has been hindered by models that incompletely reproduce the persistently inflamed lesions in which remyelination fails. Here we show that chimeric antigen receptor (CAR) T cells targeting myelin oligodendrocyte glycoprotein (MOG) build such lesions on demand. Human CD4+ CAR T cells transferred into immunodeficient mice infiltrated the brain, spinal cord, and optic nerve, producing perivascular demyelinating lesions, with reproducible optic nerve involvement. Within these discrete optic nerve lesions, treatment with the remyelinating compound clemastine reduced lesion size and improved optic nerve conduction, despite persistent inflammation. Thus, this MOG CAR T model reproduces key features of inflammatory demyelinating disease and enables testing of remyelinating therapies; more broadly, it introduces CAR T cells as programmable perturbative agents for building defined pathology in vivo.
Authors: Christian Cordano, Sasha Gupta, Caroline Guglielmetti, Chanelle Shepherd, Madison Heady, Jason Duecker, Ahmed Abdelhak, Ben Ng, Robert Zhu, Wei Yu, Sharon Sagan, David Stefanoff, Jung Sin, Alexandra Beaudry-Richard, Angelica Montevirgen, Liana Kozanno, Stephen Hauser, Michael Wilson, Scott Zamvil, Ari Green, Wendell A Lim, Milos Simic
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Award: G3097471124
OpenAlex ID: W7236223444
